Early transition from insulin to sulfonylureas in neonatal diabetes and follow-up: experience from China by Li, Xiuzhen et al.
Early transition from insulin to sulfonylureas in neonatal diabetes and follow‐up: 
experience from China 
 ABSTRACT 
Background: Sulfonylurea therapy can improve glycemic control and ameliorate 
neurodevelopmental outcomes in patients suffering from neonatal diabetes mellitus (NDM) 
with KCNJ11 or ABCC8 mutations. As genetic testing results are often delayed, it remains 
controversial whether sulfonylurea treatment should be attempted immediately at diagnosis or 
doctors should await genetic confirmation. Objective: This study aimed to investigate the 
effectiveness and safety of sulfonylurea therapy in Chinese NDM patients during infancy 
before genetic testing results were available. Methods: The medical records of NDM patients 
with their follow‐up details were reviewed and molecular genetic analysis was performed. 
Sulfonylurea transfer regimens were applied in patients diagnosed after May 2010, and 
glycemic status and side effects were evaluated in each patient. Results: There were 23 NDM 
patients from 22 unrelated families, 10 had KCNJ11 mutations, 3 
harbored ABCC8 mutations, 1 had INS mutations, 4 had chromosome 6q24 abnormalities, 1 
had a deletion at chromosome 1p36.23p36.12, and 4 had no genetic abnormality identified. 
Sixteen NDM infants were treated with glyburide at an average age of 49 days (range 14‐120 
days) before genetic confirmation. A total of 11 of 16 (69%) were able to successfully switch 
to glyburide with a more stable glucose profile. The responsive glyburide dose was 0.51 ± 
0.16 mg/kg/d (0.3‐0.8 mg/kg/d), while the maintenance dose was 0.30 ± 0.07 mg/kg/d (0.2‐
0.4 mg/kg/d). No serious adverse events were reported. Conclusions: Molecular genetic 
diagnosis is recommended in all patients with NDM. However, if genetic testing results are 
delayed, sulfonylurea therapy should be considered before such results are received, even in 
infants with newly diagnosed NDM. 
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